Increased autoantibody reactivity in plasma from Myelodysplastic Syndromes (MDS) patients may provide novel disease signatures, and possible early detection. In a two-stage study we investigated Immunoglobulin G reactivity in plasma from MDS, Acute Myeloid Leukemia post MDS patients, and a healthy cohort. In exploratory Stage I we utilized high-throughput protein arrays to identify 35 high-interest proteins showing increased reactivity in patient subgroups compared to healthy controls. In validation Stage II we designed new arrays focusing on 25 of the proteins identified in Stage I and expanded the initial cohort. We validated increased antibody reactivity against AKT3, FCGR3A and ARL8B in patients, which enabled sample classification into stable MDS and healthy individuals. We also detected elevated AKT3 protein levels in MDS patient plasma. The discovery of increased specific autoantibody reactivity in MDS patients, provides molecular signatures for classification, supplementing existing risk categorizations, and may enhance diagnostic and prognostic capabilities for MDS.
M yelodysplastic syndromes (MDS) encompass a diverse range of hematological disorders, with variable clinical outcomes resulting from individual patients' clinical and biological features 1, 2 . MDS pathogenesis involves multifaceted factors, related to intrinsic hematopoietic precursor cell abnormalities. The prevalent shared pathogenesis causing the ineffective hematopoiesis in MDS involves varying degrees of apoptosis of the hematopoietic cell linage [3] [4] [5] . Recent genomic approaches have concentrated on the effects of specific gene mutations and their associated signaling pathways, and their role in MDS development and outcome, including the tendency of transitioning to more aggressive disease stages 6, 7 . Currently, the prognosis of patient outcomes is greatly facilitated by the establishment of the International Prognostic Scoring System (IPSS 8 , recently revised as IPSS-R 9 ). The IPSS takes into account multiple clinical markers to classify lower risk patients (Low, Intermediate 1) as having improved prognoses compared to those with higher risk features (Intermediate 2 and High).
Autoantibody reactivity profiles in human plasma have been employed in multiple other disorders, including immune response in severe acute respiratory syndrome 10 , diabetes 11, 12 , as well as cancer 13, 14 using protein microarrays. In MDS patients immunologic abnormalities have been observed 15 . Furthermore, a higher rate of immune related cell abnormalities has been reported in MDS, predominantly in earlier-stage compared to later-stage MDS patients, including altered immune cell subpopulations, namely regulatory 16, 17 and inhibitory 18 T cells. Additionally, disease progression has been found to be concordant with dynamic shortening of telomeres observed in MDS precursors 19, 20 . Short telomeres and DNA damage in hematopoietic precursors, including those from MDS patients, have been associated with cellular protein secretion 21 . To further assess disease related abnormalities in autoantibody reactivity and the possibility of an immune related response in MDS patients of various stages, we have utilized high throughput protein arrays that allow the simultaneous monitoring of changes in autoantibody reactivity to thousands of human proteins. Reactive antibody profiling with protein microarray is in principle the same as Enzyme-linked Immunosorbent Assays (ELISA) with the same antigen-primary antibody-secondary antibody format, with additional advantages including 1) a higher throughput and 2) using fluorescent signals from secondary antibodies instead of the less reproducible enzyme-linked chromogenic signals. Protein microarrays have been reported to have higher throughput, sensitivity and a wider detection range compared to traditional ELISA methods in various applications 10, 22 . Our main hypothesis is that MDS elicits specific autoantibody responses, and hence we searched for autoantigen biomarkers related to various MDS patient subgroups compared to control plasmas using protein microarray technology (ProtoArrays v. 5 by Invitrogen). We focused on a retrospective classification of subjects OPEN SUBJECT AREAS: PROTEOMICS MYELODYSPLASTIC SYNDROME into stable MDS patients (s-MDS), which had not transformed into acute myeloid leukemia (AML) for at least 14 months, and generally for multiple years, transforming MDS (t-MDS), where patients eventually acquired AML within a 14-month period, and AML post MDS (L) where the patients had already transformed to AML, after previously having being classified as MDS patients 23 . The MDS and AML patients were compared to a healthy cohort of individuals.
Results
The study was conducted in two sequential separate stages: (I) The exploratory stage, in which multiple patient samples and proteins were tested for Immunoglobulin G (IgG) reactivity, and (II) the validation stage using a smaller, high-interest subset of the proteins identified in Stage I based on the retrospective classification, and expanded to a larger cohort. The use of this focused subset allowed us to utilize the proteins displaying the greatest degree of differential IgG reactivity between patient groups and healthy controls. The different experimental designs are illustrated in Fig. 1a , and described in detail with the results further below.
In Stage I multiple plasma samples (75) were obtained from male patients, in the 44-87 (median 70) age range, and a healthy cohort (34) , in the 52-70 (median 61) age range. As discussed in the Methods, the samples used in our study were obtained early in the patients' courses, to enable the assessment of predictive potential for prolonged clinical courses of the MDS patients (i.e., s-MDS). At the time of sample collection, the patients were classified using the prospective clinical risk-based IPSS system. Following long-term monitoring of the patients, the same samples were also assigned a retrospective classification (into s-MDS, t-MDS, L, as stated above and previously defined 23 ). The patients were compared to a healthy cohort (Table 1a) .
After identifying a high-priority set of 35 markers (Fig. 1b-d ) in Stage I described below, in the validation Stage II (Fig. 2a ) the initial subject pool was enlarged to include both male and female individuals, with 204 patients (119 s-MDS, 42 t-MDS, 43 L) and 112 healthy controls (Table 1b) . We note here that differences in median ages between patient and healthy groups were taken into consideration in our Analysis of Variance (ANOVA) model below to ensure they were statistically not a factor for our final results. While Stage I samples were only obtained from male patients, as prior studies in patients with ovarian and prostate carcinoma showed gender differences in antibody reactivity 13, 14 , in Stage II we assessed samples from both genders and found no such differences in our results for MDS patients.
Stage I results. The initial screening of protein arrays containing 9,483 proteins identified 35 autoantigens of high interest showing aberrantly high reactivity in patient subgroups compared to the healthy cohort (Fig. 1b) . The Venn diagram (Fig. 1c) indicates minimal overlap between the different retrospective MDS classifications, with the s-MDS group showing the greatest differences compared to the healthy group, which should be noted has greater numbers of available samples. Furthermore, considered as a whole the results support the hypothesis that MDS patients display distinct autoantibody responses compared to a healthy cohort (see also Supplementary Table S1 ).
This initial screening identified relevant molecular associations, (IngenuityH IPA Knowledge Database, http://www.ingenuity.com, Stage II results. The high-interest proteins from Stage I (see Methods for details) were tested for validation, using custom protein arrays, with 25 proteins successfully produced and spotted (Fig. 2) . To take into account multiple sources of variability, we employed an ANOVA model, and filtered results to eliminate effects due to printing, replication and batch effect, and subject age (see Methods; Fig. 3a ). We identified 3 proteins, AKT3, FCGR3A and ARL8B (Fig. 3b) , showing aberrantly increased reactivity in patients compared to healthy (P , 0.01, Bonferroni corrected), and with no other factors considered having a significant confounding effect. The corresponding binary group comparisons of mean differences were also statistically significant [Mann-Whitney U-tests, with 1) AKT3 mean intensities P , 3 [24] [25] [26] ), using the transformed intensities for AKT3, FCGR3A and ARL8B, for successful classification into retrospective classes, particularly for s-MDS ( Fig. 4a-b ). When considering s-MDS and healthy cohort only, s-MDS samples were classified correctly 87% of the time (103/119, standard deviation, s.d. ,3.1), and healthy samples at 90% (101/ 112, s.d. ,2.7). Expanding the classification to all MDS and L patients did not significantly affect classification for s-MDS or healthy cohorts (Fig. 4b) . However, the classification was lower for known t-MDS (38%, 16/42, s.d. ,3.0), and L (30%, 13/43, s.d. ,2.3) samples. Autoantibody reactivity-based classification worked less well for classifying samples into their known IPSS classes (Fig. 4c) . The best classification was for Intermediate 1(62%, 46/74 s.d, ,3.2), while the classification of healthy samples was at 100% (112/112, s.d ,0.6).
We detected all three proteins of interest in plasma using Enzymelinked Immunosorbent Assays (ELISAs). For AKT3 and FCGR3A the differential protein levels were found to be statistically significant (ANOVA analysis Bonferroni corrected P , 9 3 10 28 , ,7 3 10 25 respectively) (Fig. 3c) . For AKT3 the differential protein trend between retrospective classes reflected the autoantibody reactivity (post hoc tests, Bonferroni P , 0.01, displaying differences between all patient groups versus healthy, as well as L versus t-MDS). For FCGR3A the differential protein levels showed an opposite trend compared to the corresponding autoantibody reactivity, Fig. 3b -c (post hoc tests, Bonferroni p , 0.01 displaying differences between healthy versus both t-MDS and s-MDS, as well as between L and both t-MDS and s-MDS).
Discussion
Our investigation demonstrated differential autoantibody reactivity in MDS patient subsets, which was distinct from healthy individuals. The autoantibodies displaying increased protein reactivity compared to healthy patients included several unique proteins for t-MDS, s-MDS, and L in both the initial and validation stages (Stage I and II) of our investigation. The finding that increased antibody reactivity for these proteins predominantly occurred in s-MDS patients is consistent with prior data indicating early stage MDS having a higher degree of immune-related abnormalities than later stage patients 16, 17 . These proteins are involved in cancer-relevant biological processes such as apoptosis and have associations involving autoimmune responses. Differential reactivity of these antibodies between early stage MDS and healthy individuals also has diagnostic utility since such clinical distinctions morphologically are often difficult 27 . The three proteins validated in Stage II of our investigation present a more robust set, showing increased autoantibody reactivity in MDS patients. The detected autoantibody reactivity to the above proteins offers possible new connections between immune response and tumor formation and detection. Of these, we particularly note that AKT3 (v-akt murine thymoma viral oncogene homolog 3 /protein kinase B, gamma), has been known to be actively involved in multiple cancers, including breast cancer 28, 29 , tumorigenesis in melanomas 30, 31 , lung cancers 32 and ovarian cancers 33 (cell cycle involvement). In previous studies AKT3 gene overexpression, and deregulation of AKT pathways, have been detected by gene expression profiling 23, 34 . In addition, our observation of differential autoantibody reactivity, and corresponding protein levels, make this a compelling case for the involvement of AKT3 in MDS and highlight its potential as a biomarker for the condition in s-MDS. FCGR3A (an IgG receptor) is involved in multiple antibody processes. Fc-receptors have been the target of multiple therapeutic approaches for cancer and inflammatory states 35 , including FCGR3A 36 (genotype association to rituximab response). The FCGR3A protein levels as determined by ELISA showed an opposite trend as compared to the corresponding autoantibody reactivity. While the FCGR3A protein levels may reflect the possibility that the observed autoantibody reactivity is due to ''non-specific'' Fc-Receptor interaction rather than increased amount of specific anti-FCGR3A antibody, it does not necessarily imply a correlation between the amount of antigen and the strength of reactivity. In fact, many highly expressed proteins are not autogenic (e.g. albumin, which is a negative acute-phase protein with decreased plasma levels during immune response [37] [38] [39] ), while a small amount of allergen could trigger severe immune response. ARL8B (ADP-ribosylation factor-like 8B) is involved in lysosome trafficking and positioning, influencing mTOR expression (mammalian target of rapamycin) and autophagosome formation 40 , and may also be associated to metastasis and tumorigenesis 41 . Patient classification may be made into two separate classification schemes, prospectively by IPSS or retrospectively (s/t/L or healthy) as considered above. These classification schemes show good overlap as the IPSS Low and Intermediate 1 risk categories account for 27% and 68% respectively of our s-MDS patients (85% total). Using the autoantibody reactivities we classified patients into each of these two classification schemes (retrospective or IPSS), showing better concordance of autoantibody reactivity in stable patients with the retrospective classification rather than IPSS, but slightly lower with healthy patients (90%). As the classification into IPSS does better on healthy patients (100%), this suggests that combining the IPSS classification scheme with the autoantibody reactivities may improve clinical diagnosis of s-MDS patients while maintaining low numbers of false positives in healthy individuals. Furthermore, autoantibody reactivity-based classification relies on direct molecular marker signatures, and may have possible application as an alternative or supplement to the IPSS risk estimation, especially for early detection of s-MDS patients. Finally, the detection of autoantibody reactivity would only require plasma, and be minimally invasive for the patients.
Our study discovered differential autoantibody reactivity in MDS, and identified autoantibodies particular to prognostic MDS subsets, demonstrating that protein microarrays provide a powerful approach to identify unique biomarkers associated with this disease. In our investigation we chose the more sensitive focused protein array approach over traditional chromogenic ELISA for our validation purposes. While we envision that high-throughput, fluorescence-based methods such as protein microarrays may eventually replace traditional chromogenic ELISA in clinical tests, we expect ELISA clinical tests may also be developed in the future based on our findings. Regarding the possible specificity of our findings, although such autoantibody studies have not as yet been reported in other hematologic malignancies, the combined autoantibody reactivity we observed in our MDS patients was distinct from those reported in patients with ovarian 13 and prostate 14 cancer, diabetes 11 and after respiratory infections 10 . We expect our findings of the increased autoantibody reactivity in MDS patients with relatively prolonged clinical courses will encourage future studies with larger patient cohorts, that will be helpful to further substantiate the prognostic importance of such data and exploration of the underlying molecular mechanisms. The identified autoantibody reactivity may greatly enhance our diagnostic and prognostic capabilities for MDS. Plasma autoantibody reactivity profiling with protein arrays. In Stage I the autoantibody reactivity was profiled on the retrospective patient subsets (Table 1a) using Invitrogen ProtoArray Protein Microarrays, v5.0 (9,483 unique human proteins spotted in duplicate, 23,232 signals total including controls), as described previously 12, 13 . In parallel, duplicate negative control arrays were probed. The plasma samples were diluted 1:100 in 5 ml Washing Buffer (13 PBS, 0.1% Tween 20, 13 Roti-Block). The ProtoArrays were dried and scanned using a Genepix 4200AL Microarray Scanner (Molecular Devices, Sunnyvale, CA). The obtained array images were analyzed (Genepix Pro 6.1, Molecular Devices), obtaining feature locations, signal foreground and background intensity quantification and corresponding identification information (.gpr file format). In addition to probing for IgG reactivity (532 nm channel), the arrays were spotted with proteins containing a glutathione Stransferase (GST) fusion tag, and a second channel (635 nm) screening allowed us to probe GST intensity, which is used as a proxy for protein concentration per array spot (see also Supplementary Fig. S2) .
In Stage II a custom protein array was created to probe autoantibody reactivity in an enlarged cohort (Table 1b, Figure 2a) . Each array was produced through Invitrogen, using ProtoArray technology (Figure 2b-c) , and comprised of 12 blocks, [176 duplicated protein spots (total 352) per block]. 150 proteins from Stage I were used in analyzing protein reactivity (one subject sample per block), including 25 of the differentially reacting proteins of interest identified in Stage I, and 125 randomly selected control proteins. The probing procedure was carried out as in Stage I described above, including a negative control. The array images were analyzed as in Stage I to obtain signal information, with each block considered separately, including probing for GST intensity.
Array analyses, stage I. The arrays were analyzed in a multi-step process, involving inter-and intra-array normalization, and signal comparisons between groups to identify initially a high-interest protein set that displayed increased IgG reactivity in patient subgroups (Fig. 1a) . For each array, per channel intra-array normalization was performed via implementing the ProCAT algorithm 42 (with sliding window parameter length 15), which takes into account local background subtraction and local intensity normalization across each array. This local intensity adjustment is necessary to correct for array variations stemming from the printing and probing procedures. To adjust for probing and scanning procedure variations, inter-array intensities were quantile normalized 43 . The probed intensities were compared between all binary comparisons of patient retrospective and healthy groups. The procedure has been previously shown to be highly reproducible (R 2 . 0.89 for both technical replicates and duplicated spots 12 ). In our study we compared different patient subgroups to one another. We were specifically interested in signals showing increased reactivity in the retrospectively analyzed MDS patients versus the healthy control group, particularly s-MDS, and assessed statistical significance through a two-tailed Mann-Whitney test (Mathematica 9.0; multiple hypotheses Bonferroni adjusted P , 0.01).
After filtering control signals and protein spots inconsistently printed on the array (i.e. displaying differential GST-tag signals due to variability in array printing), a total of 35 proteins showed increased reactivity at a cutoff of P , 4 3 10 27 (Bonferroni adjusted P , 0.01) and were identified as high-interest proteins from comparisons of MDS subsets to the healthy cohort (Fig. 1b-c) . These were used for pathway and functional analysis through IPA (IngenuityH Systems, http://www.ingenuity.com), to identify relevant biological functions in the Ingenuity Knowledge Base (Fig. 1d) . To determine the probability that each biological function assigned to the data set was due to chance alone, P values were calculated using right-tailed Fisher's exact tests (P , 0.05). Additionally, canonical pathways from the IPA library that were most statistically significant were ascertained based on p-value (p , 0.05, Fisher's exact test) and ratio of molecules from the data set as compared to the total in the network (see also Supplementary Information).
Array analyses, stage II. Subsequently, in the validation stage of the study we successfully expressed 25 of these proteins onto customized focused arrays as described above. We note here that 10 proteins from the initial list of 35 candidates were not included in the validation because these could either not be successfully expressed, isolated or printed (lack of the proper clone; low viability for a specific clone; low yield in isolation, printing error, etc.) or did not pass our strict secondary quality control during selection for focused array printing, as an added measure for validation reproducibility (large GST-signal variation, negative flags raised in scanning, saturation of signal and non-reproducible variance stability in signal analysis). Additionally, the study was expanded to a much larger cohort (Table 1b) . The protein arrays were scanned as described above, with each block corresponding to a different patient, and patient samples performed in duplicates. We used the same inter-and intra-array normalization as in Stage I (Fig. 2a) , applied per block, and the signals for each protein spotted were transformed to a normal distribution using a Box-Cox transformation 44 . Each protein was analyzed using an ANOVA model 45 , checking for variance in subject subgroup (retrospective classification), replication (duplicate samples, duplicate protein spots), subject age, gender, marrow blast levels (healthy, IPSS blast categories, leukemic status), and randomization effects (batch effects between Stage I or II of the investigation), Fig. 3a . The possible interactions between all the above were also considered. Signals showing significant primary effects but no significant interactions, using Bonferroni post-hoc tests to correct for multiple group and feature comparisons, were selected as high-confidence signals of interest. Additionally, the ANOVA was used to screen out signals showing significant effects due to replication, subject age and randomization. Furthermore, to ensure that protein levels were not varying between arrays, statistically significant differential GST signals were eliminated.
Based on the ANOVA, standardized transformed reactivity levels of AKT3, ARL8B, FCGR3A were found to be higher in patients versus healthy cohort (Fig. 3b) . These proteins were then used for classifications, namely KDA (R 46 package ks 47 , using unconstrained smoothed cross-validation method for bandwidth selection) and Linear Discriminant analysis (LDA; R 46 package MASS 48 , see Supplementary Tables  S4-S6 ). KDA outperformed LDA for retrospective and IPSS classifications. Both methods involved assigning classes with 5-fold cross-validation and performing 1,000 random data partitions (Fig. 4) .
ELISAs. Utilizing ELISA kits we measured plasma levels of AKT3 (dilution 1:5, PathScanH Catalog No. #7934, Cell Signaling), FCGR3A (dilution 1:10, Catalog No. E91278Hu, Uscn Life Science Inc.) and ARL8B (dilution 1:10, MyBioSource Catalog No. MBS946943), using samples from 20 subjects (80 total) for each of s-MDS, t-MDS, L and healthy subjects tested in triplicate, following each manufacturer's instructions (Fig. 3c) .
